NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 208 filers reported holding NEKTAR THERAPEUTICS in Q3 2017. The put-call ratio across all filers is 0.25 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $898,000 | +5.9% | 25,250 | 0.0% | 0.01% | +16.7% |
| Q1 2019 | $848,000 | +2.2% | 25,250 | 0.0% | 0.01% | -14.3% |
| Q4 2018 | $830,000 | -94.9% | 25,250 | -90.5% | 0.01% | -93.9% |
| Q3 2018 | $16,170,000 | -54.1% | 265,261 | -63.2% | 0.11% | -56.7% |
| Q2 2018 | $35,209,000 | -67.3% | 721,056 | -28.9% | 0.26% | -68.3% |
| Q1 2018 | $107,740,000 | -21.3% | 1,013,932 | -55.8% | 0.83% | -20.7% |
| Q4 2017 | $136,949,000 | +57.1% | 2,293,181 | -36.9% | 1.05% | +56.1% |
| Q3 2017 | $87,178,000 | +18.2% | 3,632,419 | -3.8% | 0.67% | +6.5% |
| Q2 2017 | $73,781,000 | -22.0% | 3,773,983 | -6.4% | 0.63% | -22.5% |
| Q1 2017 | $94,597,000 | +84.1% | 4,030,539 | -3.8% | 0.81% | +80.0% |
| Q4 2016 | $51,396,000 | +12.4% | 4,188,777 | +57.4% | 0.45% | +22.2% |
| Q3 2016 | $45,718,000 | +165.1% | 2,661,104 | +119.6% | 0.37% | +159.9% |
| Q2 2016 | $17,247,000 | – | 1,212,050 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Rhenman & Partners Asset Management AB | 1,350,000 | $22,950,000 | 1.87% |
| MAVERICK CAPITAL LTD | 6,655,625 | $113,146,000 | 1.81% |
| Camber Capital Management LP | 2,500,000 | $42,500,000 | 1.49% |
| Bellevue Group AG | 3,866,258 | $65,726,000 | 0.75% |
| Adero Partners, LLC | 51,500 | $876,000 | 0.75% |
| Goodman Financial Corp | 108,342 | $1,842,000 | 0.64% |
| CM Management, LLC | 35,000 | $595,000 | 0.55% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 424,504 | $7,217,000 | 0.43% |
| RICE HALL JAMES & ASSOCIATES, LLC | 568,379 | $9,662,000 | 0.34% |
| Burleson & Company, LLC | 107,736 | $1,832,000 | 0.32% |